MediWound’s Upcoming Q2 2025 Financial Results Conference
MediWound to Report Second Quarter Financial Results
MediWound Ltd. (Nasdaq: MDWD), a leader in enzymatic therapeutics, will announce its financial results for the second quarter on a specified Thursday in August.
Conference Call and Webcast Information
In conjunction with the release, MediWound's management team will host a conference call and livestream starting at 8:30 a.m. Eastern Time, designed to discuss the financial outcomes and provide important corporate updates.
Participants can join the call by dialing the numbers listed below at least five minutes before the start time:
Conference Call & Webcast Details:
Toll-Free: 1-844-676-8833
Israel: 1-80-9212373
International: 1-412-634-6869
Webcast: Webcast Link
After the event, a recorded version of the call will be accessible for listening on MediWound’s Investor Relations webpage.
About MediWound
MediWound Ltd. is a global biotech company concentrating on the research and commercialization of enzymatic therapies emphasizing non-surgical tissue repair. Their primary product, NexoBrid, receives FDA approval for the enzymatic removal of eschar in thermal burns, currently available in various international markets, including the U.S. and Europe. Furthermore, the company is developing EscharEx, an investigational therapy aimed at chronic wound management, which has shown promising clinical results and substantial market potential.
For further details, visit www.mediwound.com and connect with us on LinkedIn.
Company Contacts
MediWound Contacts:
Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008
Frequently Asked Questions
What date will MediWound report its second quarter results?
The specific date for the financial results release will be in August.
What time is the conference call scheduled to start?
The conference call is set to start at 8:30 a.m. Eastern Time.
Where can I find the archived webcast?
The archived webcast will be available on the Investors section of MediWound's website.
What are NexoBrid and EscharEx?
NexoBrid is an FDA-approved product for burn treatment, while EscharEx is a therapy for chronic wounds, currently in late-stage development.
Who should I contact for investor relations inquiries?
For inquiries, contact Hani Luxenburg at ir@mediwound.com.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
